Litcius/Paper detail

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice

Chuangzhen Lin, Bingqing Yu, Lixin Chen, Zhaohui Zhang, Weixiang Ye, Hui Zhong, Wenke Bai, Yuping Yang, Biao Nie

2022Frontiers in Pharmacology16 citationsDOIOpen Access PDF

Abstract

Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses. Here, we investigated the role of FXR in the high-dose OCA-induced hepatoxicity in the condition of the NAFLD mouse model. Methods: Wild-type (WT) mice and FXR −/− mice were administered with over-dose OCA (0.40%) and high-dose OCA (0.16%), in a high-fat diet. RNA-seq on liver samples of mice fed with high-dose OCA was performed to dig out the prominent biological events contributing to hepatic fibrosis. Results: Over-dose OCA induced liver injury and shortened survival in WT mice, but not FXR −/− mice. High-dose OCA caused hepatic stellate cell activation and liver fibrosis in the presence of FXR. Furthermore, high-dose OCA induced cholesterol accumulation in livers via the upregulation of genes involved in cholesterol acquisition and downregulation of genes regulating cholesterol degradation in liver, leading to the production of interleukin -1β and an FXR-mediated inflammatory response. Conclusion: The high-dose OCA induced FXR-dependent hepatic injury via cholesterol accumulation and interleukin -1β pathway in the NAFLD mice.

Topics & Concepts

Farnesoid X receptorObeticholic acidNonalcoholic fatty liver diseaseDownregulation and upregulationInternal medicineEndocrinologyLiver X receptorLiver injuryMedicineNuclear receptorPeroxisome proliferator-activated receptorAgonistHepatic stellate cellCholesterolPharmacologyReceptorChemistryFatty liverTranscription factorDiseaseBiochemistryGeneLiver Disease Diagnosis and TreatmentDrug Transport and Resistance MechanismsLiver Diseases and Immunity